Diagnóstico de mieloma múltiple
Multiple myeloma is a malignant disease characterized by the abnormal proliferation of plasma cells, the prognosis of patients with this disease is highly variable, with a median survival of 2.5 to 3 years, the average age of their condition is around 65 years old. Only 12 percent and 3 percent of p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2022
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=8374650 |
| Source: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 133-142 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|
| Summary: |
Multiple myeloma is a malignant disease characterized by the abnormal proliferation of plasma cells, the prognosis of patients with this disease is highly variable, with a median survival of 2.5 to 3 years, the average age of their condition is around 65 years old. Only 12 percent and 3 percent of patients are under 50 and 40 years old, respectively. The methodology used for this research work is framed within a bibliographic review of documentary type, since we are going to deal with issues raised at a theoretical level such as Diagnosis of multiple myeloma. The technique for data collection is made up of electronic materials, the latter such as Google Scholar, PubMed, among others, relying on the use of descriptors in health sciences or MESH terminology. The information obtained here will be reviewed for further analysis. We can conclude within what was analyzed in the development of this research, that multiple myeloma is a chronic condition, and that despite the fact that there are different types of treatments, it is incurable, at least so far, despite the combination of different drugs and existing transplants, what these treatments do is prolong the life of patients, for a period so far no longer than 5 years in most cases and one of the predominant factors in the outcome of this disease it is age, since it affects people over 60 years of age associated with comorbidities that may worsen prognosis and survival, and risk factors associated so far with exposure to radiation and chemical substances, supported by international studies. As for the diagnosis, like the rest of the diseases, it has an initial physical assessment, followed by laboratory tests and images that confirm it. |
|---|